Bio-Rad Laboratories (BIO-B) Net Cash Flow Growth (5y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Bio-Rad Laboratories | - | - | 309.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.36% |
| Dec 31, 2025 | 22.12% |
| Sep 30, 2025 | -35.47% |
| Jun 30, 2025 | -199.05% |
| Mar 31, 2025 | 22.23% |
| Dec 31, 2024 | -6.37% |
| Sep 30, 2024 | 23.00% |
| Jun 30, 2024 | -17.50% |
| Mar 31, 2024 | 3.62% |
| Dec 31, 2023 | -75.88% |
| Sep 30, 2023 | 15.03% |
| Jun 30, 2023 | -57.17% |
| Mar 31, 2023 | 5.85% |
| Dec 31, 2022 | -25.36% |
| Sep 30, 2022 | -58.38% |
| Jun 30, 2022 | -60.95% |
| Mar 31, 2022 | 31.66% |
| Dec 31, 2021 | -59.28% |
| Sep 30, 2021 | 162.30% |
| Jun 30, 2021 | 22.51% |
| Mar 31, 2021 | 18.22% |
| Dec 31, 2020 | -33.53% |
| Sep 30, 2020 | 31.75% |
| Jun 30, 2020 | -47.08% |
| Mar 31, 2020 | -114.03% |
| Dec 31, 2019 | 79.64% |
| Sep 30, 2019 | -18.31% |
| Jun 30, 2019 | 43.22% |
| Mar 31, 2019 | -7.77% |
| Dec 31, 2018 | -37.99% |
| Sep 30, 2018 | 18.98% |
| Jun 30, 2018 | -8.75% |
| Mar 31, 2018 | 17.74% |
| Dec 31, 2017 | 14.70% |
| Sep 30, 2017 | 18.74% |
| Jun 30, 2017 | 18.39% |
| Mar 31, 2017 | -28.53% |
| Dec 31, 2016 | 20.23% |
| Sep 30, 2016 | 19.27% |
| Jun 30, 2016 | -7.36% |
| Mar 31, 2016 | 26.59% |
| Dec 31, 2015 | -16.69% |
| Sep 30, 2015 | 45.93% |
| Jun 30, 2015 | 0.47% |
| Mar 31, 2015 | 15.11% |
| Dec 31, 2014 | -15.54% |
| Sep 30, 2014 | 23.38% |